ArticleCOPD2014
Intravenous and intratracheal mesenchymal stromal cell injection in a mouse model of pulmonary emphysema.
Article in COPD, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis.Cells · 2022Pooled it
- Pooled it
- Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels.Respiratory research · 2021Trial
- Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells.Frontiers in immunology · 2024Review
- Classical monocyte-derived macrophages as therapeutic targets of umbilical cord mesenchymal stem cells: comparison of intratracheal and intravenous administration in a mouse model of pulmonary fibrosis.Respiratory research · 2023Article
- Human Umbilical Cord-Derived Mesenchymal Stem Cells Repair SU5416-Injured Emphysema by Inhibiting Apoptosis via Rescuing VEGF-VEGFR2-AKT Pathway in Rats.International journal of stem cells · 2022Article
- Systemic administration of c-KitBMC molecular and cell biology · 2022Article
- Cellular Immunotherapy and the Lung.Vaccines · 2021Review
- Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.Respiratory research · 2021Article
- Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis.Frontiers in cell and developmental biology · 2021Review
- Effects of Wharton's jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease.Regenerative therapy · 2019Article
- Cell-based Therapy for Chronic Obstructive Pulmonary Disease. Rebuilding the Lung.Annals of the American Thoracic Society · 2018Review
- Impact of one versus two doses of mesenchymal stromal cells on lung and cardiovascular repair in experimental emphysema.Stem cell research & therapy · 2018Article
- Activation of p70S6 Kinase-1 in Mesenchymal Stem Cells Is Essential to Lung Tissue Repair.Stem cells translational medicine · 2018Article
- Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?Thorax · 2018Review
- Article
- Can Youthful Mesenchymal Stem Cells from Wharton's Jelly Bring a Breath of Fresh Air for COPD?International journal of molecular sciences · 2017Review
- Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.World journal of stem cells · 2017Review
- Mesenchymal stromal cell therapy in COPD: from bench to bedside.International journal of chronic obstructive pulmonary disease · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to characterize the evolution of lung function and -structure in elastase-induced emphysema in adult mice and the effect of mesenchymal stromal cell (MSC) administration on these parameters. Adult mice were treated with intratracheal (4.8 units/100 g bodyweight) elastase to induce emphysema. MSCs were administered intratracheally or intravenously, before or after elastase injection. Lung function measurements, histological and morphometric analysis of lung tissue were performed at 3 weeks, 5 and 10 months after elastase and at 19, 20 and 21 days following MSC administration. Elastase-treated mice showed increased dynamic compliance and total lung capacity, and reduced tissue-specific elastance and forced expiratory flows at 3 weeks after elastase, which persisted during 10 months follow-up. Histology showed heterogeneous alveolar destruction which also persisted during long-term follow-up. Jugular vein injection of MSCs before elastase inhibited deterioration of lung function but had no effects on histology. Intratracheal MSC treatment did not modify lung function or histology. In conclusion, elastase-treated mice displayed persistent characteristics of pulmonary emphysema. Jugular vein injection of MSCs prior to elastase reduced deterioration of lung function. Intratracheal MSC treatment had no effect on lung function or histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.